Trials / Completed
CompletedNCT04011670
Neuroplastic Alterations of the Motor Cortex by Caffeine
Neuroplastic Alterations of the Motor Cortex by Caffeine: Differences Between Caffeine and Non-caffeine Users and Influence of Vigilance During Stimulation
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University Medical Center Goettingen · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Caffeine is a psychostimulant drug. It acts as a competitive antagonist at adenosine receptors, which modulate cortical excitability as well. In deep brain stimulation (DBS), the production of adenosine following the release of adenosine triphosphate (ATP) explains the reduction of tremor. Binding of adenosine to adenosine A1 receptors suppresses excitatory transmission in the thalamus and hereby reduces both tremor-and DBS-induced side effects. Also, the effect of adenosine was attenuated following the administration of the 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) adenosine A1 receptor antagonist. Therefore, the presence of a receptor antagonist such as caffeine was suggested to reduce the effectiveness of deep brain stimulation (DBS) in treating tremor and other movement disorders. Based on this finding, the investigators hypothesize that the antagonistic effect of caffeine can tentatively block the excitatory effects of transcranial alternating current stimulation (tACS). The plasticity effects might differ among caffeine users and non- caffeine users depending on the availability of receptor binding sites. Apart from that, a major issue in NIBS studies including those studying motor-evoked potentials is the response variability both within and between individuals. The trial to trial variability of motor evoked potentials (MEPs) may be affected by many factors. Inherent to caffeine is its effect on vigilance. In this study, the investigator shall monitor the participant's vigilance by pupillometry to (1) better understand the factors, which might cause variability in transcranial excitability induction studies and (2) to separate the direct pharmacological effect from the indirect attentional effect of caffeine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 200 mg caffeine tablet | * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition * Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition * Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition |
| OTHER | Non-active tablet | * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition * Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition * Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition |
Timeline
- Start date
- 2019-07-15
- Primary completion
- 2019-11-19
- Completion
- 2019-11-19
- First posted
- 2019-07-08
- Last updated
- 2019-11-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04011670. Inclusion in this directory is not an endorsement.